Literature DB >> 28626517

Janus-Associated Kinase 1 (JAK1) Inhibitors as Potential Treatment for Immune Disorders.

Ahmed F Abdel-Magid1.   

Abstract

Entities:  

Year:  2017        PMID： 28626517      PMCID： PMC5467203          DOI： 10.1021/acsmedchemlett.7b00209

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


× No keyword cloud information.
  3 in total

Review 1.  Progress toward JAK1-selective inhibitors.

Authors:  Christel J Menet; Oscar Mammoliti; Miriam López-Ramos
Journal:  Future Med Chem       Date:  2015       Impact factor: 3.808

Review 2.  Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis.

Authors:  Shingo Nakayamada; Satoshi Kubo; Shigeru Iwata; Yoshiya Tanaka
Journal:  BioDrugs       Date:  2016-10       Impact factor: 5.807

Review 3.  Evaluation of WO-2013040863, WO-2013041042 and WO-2013043962. Selective JAK1 inhibitors based on a 3-aminopyrazole-4-carboxamide scaffold.

Authors:  Peter Norman
Journal:  Expert Opin Ther Pat       Date:  2013-11-22       Impact factor: 6.674
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.